Botox [保妥適] - Taiwan - 全球药品采购网

TOP

Botox [保妥適]

2014-04-23 22:38:32 来源: 作者: 【大中小】浏览:646次评论:0条

全民健康保險藥品給付規定 / 健保碼及健保價

See related Botox powd for inj[保妥適乾粉注射劑] information

製造商

Allergan

代理/經銷商

Allergan

成份

Botulinum toxin type A

適應症

For the treatment of strabismus & blepharospasm associated with dystonia, including benign essential blepharospasm or VII nerve disorders in patients ≥ 12 years. Treatment of spasmodic torticollis (cervical dystonia) in adults. Treatment of dynamic equinus foot deformity due to spasticity in pediatric cerebral palsy patients ≥ 2 years. Treatment of primary hyperhidrosis of the axilla. Treatment of glabellar lines associated with corrugator &/or procerus muscle activity. Management of focal spasticity, including treatment of upper limb spasticity associated with stroke in adults.

用量

Cervical dystonic (spasmodic torticollis) Dosing based on patient's head & neck position, localization of pain, muscle hypertrophy, body weight & response. Usual range: 95-360 u. Strabismus For vertical muscles & for horizontal strabismus of < 20 prism diopters: 1.25-2.5 u in any 1 muscle. For horizontal strabismus of 20-50 prism diopters: 2.5-5 u in any 1 muscle. For persistent VI nerve palsy of ≥ 1 month: 1.25-2.5 u in the medial rectus muscle. Max: 25 u as single inj for any 1 muscle. Blepharospasm Initially 1.25-2.5 u injected into the medial & lateral pre-tarsal orbicularis oculi of the upper lid & into the lateral pre-tarsal orbicularis oculi of the lower lid. Max cumulative dose: 200 u/2 months. Duration of treatment: 3 months. May repeat procedure & increase dose up to 2-fold if effect does not last for > 2 months. VII nerve disorders Patients with hemifacial spasm or VII nerve disorder should be treated as for unilateral blepharospasm. Max cumulative dose: ≤ 200 u/2 months. Spasticity (due to juvenile cerebral palsy) 4 u/kg into each of 2 sites in the medial & lateral heads of the gastrocnemius muscle of the affected lower limb(s). Primary hyperhidrosis of the axillae 50 u intradermally to each axilla evenly distributed in multiple sites about 1-2 cm apart. Treatment may be repeated every 2 months or more. Glabellar lines 4 u into each of 5 sites, 2 in each corrugator muscle & 1 in the procerus muscle for a total dose of 20 u. Focal spasticity associated with stroke Max 360 u divided among selected muscles (typically the flexor muscles of the elbow, wrist & fingers) at any treatment session. Repeat dose at 12-16 weeks interval.

過量

View Botox[保妥適] overdosage for action to be taken in the event of an overdose.

美國食品藥物管理局之懷孕等級

Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus.

禁忌

Myasthenia gravis or Eaton Lambert syndrome, infection at inj site.

注意事項

Amyotrophic lateral sclerosis, disorders causing acetylcholine depletion at the neuromuscular junction, sedentary patients, inflammation at proposed inj site, excessive weakness in the target muscles, patient at risk of angle-closure glaucoma. Pregnancy, lactation.

不良反應

Localized pain, tenderness &/or bruising, local weakness. Rarely, skin rash (including erythema multiforme, urticaria & psoriasiform eruption), pruritus, allergic reactions, dysphagia, pneumonia.
View ADR Monitoring Website[參閱藥物不良反應監測表格]

交互作用

Aminoglycosides or other medications which interfere with neuromuscular transmission.
View more drug interactions with Botox[保妥適]

使用上注意

For caution against possible variation of physical aspect of medicine... click to view Botox[保妥適] detailed prescribing infomation

儲存

View Botox[保妥適] storage conditions for details to ensure optimal shelf-life.

描述

View Botox[保妥適] description for details of the chemical structure and excipients (inactive components).

作用

View Botox[保妥適] mechanism of action for pharmacodynamics and pharmacokinetics details.

本商品之市售規格

劑型